Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of AHU377 with valsartan in mild-to-moderate systolic hypertension
2010-022326-32Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril and valsartan in essential hypertension (6 arms), sponsored by Novartis. Primary endpoint: Dose-response relationship in mean sitting systolic blood pressure. Started Oct 2010; status: completed.
02
Drugs
sacubitrilvalsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2010-022326-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022326-32.